Stocksigma LogoStocksigma Logo

Suven Life Sciences to Present Pipeline Progress at CTAD 2026

Suven Life Sciences will present clinical updates on Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107) at the CTAD conference from 16th to 19th Nov'26 in

Suven Life Sciences to Present Pipeline Progress at CTAD 2026

Suven Life Sciences Ltd 路 Press Release 路 16 Nov 2026, 5:51 pm

Suven Life Sciences to Present Pipeline Progress at CTAD 2026 Suven Life Sciences will present clinical updates on Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107) at the CTAD conference from 16th to 19th Nov'26 in Boston. Patient enrollment is complete for Masupirdine鈥檚 global Phase-3 study targeting agitation in Alzheimer鈥檚 dementia, with no major safety concerns reported and topline results anticipated in Q2'27. Additionally, Phase-1 SAD and MAD data for Tenaclidine demonstrated positive safety, tolerability, and pharmacokinetic profiles in healthy subjects, supporting its planned advancement into patient-level clinical studies for cognitive disorders.

Original exchange filing (PDF)

More announcements from Suven Life Sciences Ltd

All Suven Life Sciences Ltd announcements